| Literature DB >> 34041297 |
Aimen El Orche1, Casimir Adade Adade2, Hafid Mefetah3, Amine Cheikh4, Khalid Karrouchi2, Miloud El Karbane2, Mustapha Bouatia2.
Abstract
In clinical treatment, the analytical quality assessment of the delivery of chemotherapeutic preparations is required to guarantee the patient's safety regarding the dose and most importantly the appropriate anticancer drug. On its own, the development of rapid analytical methods allowing both qualitative and quantitative control of the formulation of prepared solutions could significantly enhance the hospital's workflow, reducing costs, and potentially providing optimal patient care. UV-visible spectroscopy is a nondestructive, fast, and economical technique for molecular characterization of samples. A discrimination and quantification study of three chemotherapeutic drugs doxorubicin, daunorubicin, and epirubicin was conducted, using clinically relevant concentration ranges prepared in 0.9% NaCl solutions. The application of the partial least square discriminant analysis PLS-DA method on the UV-visible spectral data shows a perfect discrimination of the three drugs with a sensitivity and specificity of 100%. The use of partial least square regression PLS shows high quantification performance of these molecules in solution represented by the low value of root mean square error of calibration (RMSEC) and root mean square error of cross validation (RMSCECV) on the one hand and the high value of R-square on the other hand. This study demonstrated the viability of UV-visible fingerprinting (routine approach) coupled with chemometric tools for the classification and quantification of chemotherapeutic drugs during clinical preparation.Entities:
Year: 2021 PMID: 34041297 PMCID: PMC8121585 DOI: 10.1155/2021/5580102
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Molecular structure representation of the three drugs of the anthracycline family.
Figure 2Graphical representation of the UV-visible absorption spectra of the three molecules.
Figure 3PCA score plot results of two principal components (PC1-PC3).
Figure 43D-PLS-DA score plot for the UV-visible spectra of the three chemotherapy drugs.
Statistical parameters of the PLS-DA model.
| Label | Number of latent variable | Calibration | Crossvalidation | ||
|---|---|---|---|---|---|
|
| RMSEC |
| RMSECV | ||
| Doxorubicin | 7 LV | 0.99 | 0.05 | 0.97 | 0.08 |
| Daunorubicin | 0.98 | 0.07 | 0.96 | 0.09 | |
| Epirubicin | 0.99 | 0.04 | 0.98 | 0.06 | |
Confusion matrix for the classification of anthracycline drugs (1: doxorubicin, 2: daunorubicin, and 3: epirubicin) using the PLS-DA method.
| Confusion matrix | Actual set | ||||||
|---|---|---|---|---|---|---|---|
| Label | 1 | 2 | 3 | Specificity % | Sensitivity% | %CCR | |
| Predicted training set | 1 | 22 | 0 | 0 | 100 | 100 | 100 |
| 2 | 0 | 15 | 0 | ||||
| 3 | 0 | 1 | 15 | ||||
Performance results of the quantification models developed for all concentration ranges of the three drugs.
| Doxorubicin | Daunorubicin | Epirubicin | |
|---|---|---|---|
| Concentration range mg/mL | 0.001-0.064 | 0.006-0.077 | 0.006-0.083 |
| Spectral pretreatment | Raw | Raw | Raw |
| Number of variables latent | 1 | 1 | 1 |
|
| 0.99 | 0.99 | 0.99 |
|
| 0.99 | 0.99 | 0.99 |
| RMSECV | 0.00037 | 0.00179 | 0.00125 |
| RMSEC | 0.00033 | 0.00162 | 0.00089 |
Figure 5Actual values vs. predicted values using PLS regression ((a) doxorubicin, (b) daunorubicin, and (c) epirubicin).